Trial intelligence / Profile preview

Methylphenidate N-of-1 series in adults with phenylketonuria and ADHD

NL-OMON24320Not yet recruiting

Sponsor
Amsterdam University Medical Center
Start
Sep 2021
Modality
Small Molecules
Countries
1
01

Overview

Randomised, double-blind trial of methylphenidate in attention deficit hyperactivity disorder (ADHD), sponsored by Amsterdam University Medical Center. Primary endpoint: Goal Attainment Scaling. Planned start Sep 2021; status: not yet recruiting.

02

Drugs

methylphenidate
03

Conditions

attention deficit hyperactivity disorder (ADHD)

Beyond the preview

Go deeper on NL-OMON24320.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NL-OMON24320.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call